KAYEXALATE Rx

Select the drug indication to add to your list

KAYEXALATE

Poisoning/overdose
Only 4 drugs may be compared at once

Generic Name and Formulations:

Sodium polystyrene sulfonate; pwd; sodium content 4.1mEq/g.

Select therapeutic use:

Indications for KAYEXALATE:

Hyperkalemia.

Limitations Of use:

Not for treating life-threatening hyperkalemia due to its delayed onset of action.

Adult:

See full labeling. Oral: give in an upright position; 15g as a suspension 1–4 times daily. Rectal enema: 30–50g in 100mL every 6hrs.

Children:

See full labeling. 1g per 1mEq of potassium as basis of calculation may be used.

Contraindications:

Obstructive bowel disease. Neonates with reduced gut motility.

Warnings/Precautions:

Avoid in patients at risk for constipation/impaction (eg, history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, bowel obstruction); discontinue if constipation develops. Post-surgery: avoid if have not had a bowel movement. CHF, hypertension, edema: monitor for fluid overload. Risk of aspiration. Monitor electrolytes (eg, potassium, calcium, magnesium). Neonates: do not give by oral route. Infants.

Interactions:

Increased risk of intestinal necrosis with concomitant sorbitol; not recommended. Separate dosing by ≥3hrs before or ≥3hrs after other oral drugs (6hrs in patients with gastroparesis). Increased risk of systemic alkalosis with nonadsorbable cation-donating antacids and laxatives. Reduces absorption of thyroxine, lithium.

Pharmacological Class:

Cation exchange resin.

Adverse Reactions:

Anorexia, constipation, diarrhea, fecal impaction, GI concretions (bezoars), ischemic colitis, nausea, vomiting; intestinal necrosis, electrolyte disturbances.

How Supplied:

Jar (453g)—1

KAYEXALATE 454g can of powders (Qty:1)

appx. price $804.00